news
Philippine FDA Circular Updates ASEAN Cosmetic Directive Rules

The Philippine Food and Drug Administration has issued Circular No. 2026-0001, consolidating amendments to the ASEAN Cosmetic Directive (ACD) adopted during the 40th, 41st and 42nd meetings of the ASEAN Cosmetic Committee (ACC) and related sessions, according to a notice tracked by Google News.
The circular's title identifies it as a consolidation exercise, meaning the Philippine FDA is folding several rounds of ACC-level decisions into a single domestic reference document rather than issuing one new standalone rule. The public summary reviewed by HTT News does not itemize which specific ingredient lists, labeling requirements or annex provisions changed during the 40th through 42nd ACC meetings. The agency's own circular text, once published, would carry that detail.
What is the ASEAN Cosmetic Directive?
The ACD is the regional framework ASEAN member states use to align cosmetic product requirements, including ingredient restrictions and labeling, across the bloc. The Philippines, as an ASEAN member, incorporates ACC-adopted changes into national FDA circulars so that cosmetics sold domestically track the regional standard. Circular No. 2026-0001 is that incorporation step for the amendments adopted across the three most recent ACC meeting cycles.
Which ACC meetings does the circular cover?
The circular groups together decisions from three numbered ACC meetings — the 40th, 41st and 42nd — plus what the title describes as "their related meetings." Grouping multiple meeting cycles into one circular is consistent with how the Philippine FDA has periodically consolidated ACD updates rather than issuing a circular after every single ACC session.
By the numbers
- Circular number: 2026-0001, the first circular the Philippine FDA has issued under that numbering sequence for 2026.
- Meeting range covered: three consecutive ASEAN Cosmetic Committee meetings, numbered 40th through 42nd, plus related sessions.
How did this circular come together?
- 40th ACC meeting: First of the three sessions whose decisions are folded into the consolidated circular.
- 41st ACC meeting: Second session in the covered range.
- 42nd ACC meeting and related meetings: Final session in the range, plus associated technical sessions referenced in the circular title.
- Circular No. 2026-0001: Philippine FDA publication consolidating the above into one domestic issuance.
The source material reviewed does not specify calendar dates for any of the three ACC meetings or for the circular's publication beyond the 2026 numbering prefix.
What should cosmetics brands and consumers watch for?
- Whether the Philippine FDA publishes the full annex text showing which ingredients, labeling rules or product categories changed.
- Any compliance or transition deadline the agency sets for manufacturers and importers to align with the amended ACD provisions.
- Whether retailers update product labeling in response, a process consumers can track by checking ingredient lists against established skincare reference points such as the distinction between retinol and retinal, two active-ingredient terms that often appear in regional labeling disputes.
- Statements from industry associations or retailers once the full circular text circulates publicly.
Why does a consolidated circular matter to shoppers?
For consumers, ACD-linked circulars typically translate into updated ingredient permissions, concentration limits or labeling language on cosmetics sold in the Philippine market. Because the circular reviewed here consolidates three meeting cycles' worth of decisions at once, any resulting label or formulation changes could appear across a wider swath of products than a single-meeting update would produce. Shoppers evaluating a new or reformulated product in the coming months can cross-check active ingredients against general skincare guidance, including science-backed tips for building a skincare routine, while the Philippine FDA's full circular text works through publication.
HTT News found no statement in the available source material from the Philippine FDA, ASEAN Cosmetic Committee, or industry groups characterizing the amendments' substance or timeline beyond the circular's title. Readers seeking the underlying annex changes should consult the Philippine FDA's official circular once it is posted through the agency's standard publication channels, since the specific technical content was not detailed in the notice reviewed for this report.
The circular's numbering — 2026-0001 — indicates it is the Philippine FDA's first circular issued under that sequence this year, a marker that typically signals priority placement early in the agency's annual issuance calendar but does not by itself indicate the scope of the underlying rule changes.
Questions
What does FDA Circular No. 2026-0001 do?
It consolidates amendments to the ASEAN Cosmetic Directive adopted during the 40th, 41st and 42nd ASEAN Cosmetic Committee meetings and related sessions into one Philippine FDA issuance.
Which ASEAN Cosmetic Committee meetings are covered?
The circular groups decisions from three consecutive meetings, numbered 40th through 42nd, along with related meetings referenced in the circular's title.